Immunome to Present at Upcoming Investor Conferences Feb 23, 2026 08:00AM
Immunome prices $400 million public stock offering at $21.50 per share Dec 16, 2025 08:16PM
Immunome Announces Pricing of Public Offering of Common Stock Dec 16, 2025 08:16PM
Immunome announces $400 million public stock offering Dec 15, 2025 04:01PM
Immunome Announces Proposed Public Offering of Common Stock Dec 15, 2025 04:01PM


May 22, 2025 08:00AM Immunome to Present at Upcoming Investor Conferences 
Feb 25, 2025 08:00AM Immunome to Present at Upcoming March Conferences
Jan 31, 2025 04:01PM Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jan 30, 2025 07:22AM Immunome Inc. (IMNM) Prices Upsized Public Offering of Common Stock at $7.75/Each
Jan 29, 2025 11:11PM Immunome Announces Pricing of Upsized Public Offering of Common Stock
Jan 29, 2025 04:27PM Immunome Inc. (IMNM) Announces Proposed $125M Share Offering
Jan 29, 2025 04:27PM Immunome Announces Proposed Public Offering of Common Stock
Sep 16, 2024 08:54AM TD Cowen Reiterates Buy Rating on Immunome Inc. (IMNM)
Aug 13, 2024 09:49AM TD Cowen Reiterates Buy Rating on Immunome Inc. (IMNM)
Mar 1, 2024 08:00AM Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Feb 16, 2024 04:05PM Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Feb 14, 2024 05:47AM Immunome (IMNM) Prices 10M Share Offering at $20/sh
Feb 13, 2024 10:38PM Immunome Announces Pricing of Public Offering of Common Stock
Feb 13, 2024 04:05PM Immunome Inc. (IMNM) Announces Proposed $200M Share Offering
Feb 13, 2024 04:05PM Immunome Announces Proposed Public Offering of Common Stock
Jun 29, 2023 09:01AM Immunome Inc. (IMNM) and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million
Jun 29, 2023 09:00AM Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies